Inhibition of pancreatic lipase by berberine and dihydroberberine: an investigation by docking simulation and experimental validation

[1]  M. Hudaib,et al.  A potential role of Lavandula angustifolia in the management of diabetic dyslipidemia , 2011 .

[2]  M. Hudaib,et al.  Screening of Some Medicinal Plants for their Pancreatic Lipase Inhibitory Potential , 2011 .

[3]  M. Hudaib,et al.  Pancreatic lipase inhibition activity of trilactone terpenes of Ginkgo biloba , 2011, Journal of enzyme inhibition and medicinal chemistry.

[4]  M. Hudaib,et al.  Inhibition of hormone sensitive lipase and pancreatic lipase by Rosmarinus officinalis extract and selected phenolic constituents , 2010 .

[5]  P. R. Vuddanda,et al.  Berberine: a potential phytochemical with multispectrum therapeutic activities , 2010, Expert opinion on investigational drugs.

[6]  G. Davies,et al.  Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. , 2010, Fitoterapia.

[7]  M. Lane,et al.  Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. , 2009, American journal of physiology. Endocrinology and metabolism.

[8]  S. Panigrahi,et al.  Obesity: pathophysiology and clinical management. , 2009, Current medicinal chemistry.

[9]  Jayaraman Chandrasekhar,et al.  Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective. , 2008, Drug discovery today.

[10]  K. Bhutani,et al.  Pancreatic lipase inhibitors from natural sources: unexplored potential. , 2007, Drug Discovery Today.

[11]  Y. Aggoun,et al.  Obesity, Metabolic Syndrome, and Cardiovascular Disease , 2007, Pediatric Research.

[12]  Dunstan Cooke,et al.  The obesity pipeline: current strategies in the development of anti-obesity drugs , 2006, Nature Reviews Drug Discovery.

[13]  D. James,et al.  Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States , 2006, Diabetes.

[14]  D. Cummings,et al.  Emerging therapeutic strategies for obesity. , 2006, Endocrine reviews.

[15]  J. Halford.  Obesity drugs in clinical development. , 2006, Current opinion in investigational drugs.

[16]  Mutasem O. Taha,et al.  Berberine potently inhibits protein tyrosine phosphatase 1B: Investigation by docking simulation and experimental validation , 2006, Journal of enzyme inhibition and medicinal chemistry.

[17]  E. Cairns.  Obesity: the fat lady sings? , 2005, Drug discovery today.

[18]  Satoru Inaba,et al.  Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins , 2004, Nature Medicine.

[19]  C. Arbeeny.  Addressing the unmet medical need for safe and effective weight loss therapies. , 2004, Obesity research.

[20]  Yuguang Shi,et al.  Lipid metabolic enzymes: emerging drug targets for the treatment of obesity , 2004, Nature Reviews Drug Discovery.

[21]  M. Mukherjee.  Human digestive and metabolic lipases—a brief review , 2003 .

[22]  K. Hofbauer.  Molecular pathways to obesity , 2002, International Journal of Obesity.

[23]  W. Weiss.  Pharmacotherapy for obesity. , 2002, The New England journal of medicine.

[24]  S. Peikin,et al.  Orlistat: its current status as an anti-obesity drug. , 2002, European journal of pharmacology.

[25]  George A. Bray,et al.  Medicinal strategies in the treatment of obesity , 2000, Nature.

[26]  L. Sjöström,et al.  Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[27]  H. van Tilbeurgh,et al.  The 2.46 A resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl phosphonate. , 1994, Biochemistry.

[28]  H. Tilbeurgh,et al.  Structure of the pancreatic lipase–procolipase complex , 1992, Nature.

[29]  F. Winkler,et al.  Structure of human pancreatic lipase , 1990, Nature.